New Market - January 12, 2026
Novo Nordisk’s Wegovy pill now broadly available across America
Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
Acquisition - December 14, 2025
Sobi to acquire Arthrosi Therapeutics
Sobi will pay USD 950 million upfront in cash to acquire Arthrosi, together with up to USD 550 million in cash in clinical, regulatory and sales milestones.
Agreement - December 11, 2025
Nanexa and Moderna enter into license and option agreement
Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.
Acquisition - December 10, 2025
LINK Medical transfers selected operations previously part of SDS Life Science
LINK Medical has announced the transfer of specific business areas from SDS Life Science (an affiliate of Cytel), namely the Drug Development Consulting and Clinical Project Management/Medical Writing units.
Pharma Business - December 9, 2025
Xinnate receives FDA IND approval
The US Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for TCP-25, a novel topical immunomodulatory peptide being developed for the treatment of Epidermolysis Bullosa (EB).
New Market - December 9, 2025
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing
Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).